title: [Treatment of moderate-severe psoriasis with etanercept in patients with chronic human immunodeficiency virus infection].
abstract: Cutaneous and articular psoriasis usually have a more complicated course in patients chronically infected by human immunodeficiency virus (HIV), not only for its particular presentation in these subjects, but also because of their modified immunological scenario and potential drugs interactions with antiretroviral therapy. Because of tumor necrosis factor (TNF) downregulation may improve the evolution of chronic infections, some authors support biological TNF blockers as an effective and safe therapeutical approach for the treatment of psoriasis in patients with HIV infection. We present the case of a man with cutaneous and articular psoriasis and chronic HIV infection who responded successfully to etanercept, and we make a review of the literature. There were no adverse events or changes in CD4+ lymphocyte and viral load all along the treatment.
authors.affiliation: Servicio de Dermatología, Hospital de la Santa Creu i Sant Pau, Barcelona, España. dbarco@santpau.cat
authors.forename: D
authors.initials: D
authors.lastname: Barco
authors.forename: L
authors.initials: L
authors.lastname: Puig
authors.forename: A
authors.initials: A
authors.lastname: Alomar
mesh_terms: D000068800:Etanercept; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept